Ruben A Mesa MD FACP
Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
President, Levine Cancer Institute & Enterprise Cancer Service Line Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center Enterprise Senior Vice President, Atrium Health Vice Dean for Cancer Programs, Wake Forest University School of Medicine Professor of Medicine, Wake Forest University School of Medicine
Join to view full profile
1021 Morehead Medical DrSte ACharlotte, NC 28204
Phone+1 980-442-2000
Dr. Mesa is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Ruben Mesa, MD, based in Charlotte, NC, is a hematologist specializing in hematologic oncology and myeloproliferative disorder hematology-oncology. He graduated in 1995 from Mayo Clinic College of Medicine and completed his residency in internal medicine and fellowship in hematology and medical oncology there. Currently, he serves as Executive Director at Wake Forest Baptist Health and President at Levine Cancer Institute, having previously held leadership roles at UT Health San Antonio MD Anderson Cancer Center and Mayo Clinic. His expertise includes amyloidosis, eosinophilia, and myeloproliferative disorders, and he has published multiple papers on related topics. Dr. Mesa's clinical trial involvement includes studies on chemotherapy drugs and treatments for myelofibrosis. He has received several CMS Meaningful Use Stage 1 Certifications from Cerner Corporation.
Education & Training
Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1998 - 2002- Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995 - 1998
- Mayo Clinic College of MedicineClass of 1995
Certifications & Licensure
TX State Medical License 2017 - 2028
AZ State Medical License 2009 - 2027
NC State Medical License 2023 - 2027
MN State Medical License 1996 - 2013
American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2013, 2015
- CMS Meaningful Use Stage 1 Certification FirstNet (Clinical), Cerner Corporation, 2013, 2015
- CMS Meaningful Use Stage 1 Certification FirstNet (Image Results), Cerner Corporation, 2013, 2015
Clinical Trials
Publications & Presentations
PubMed
- Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EX...Brandi N Reeves, Firas El Chaer, Lynda Foltz, Tsewang Tashi, Ghaith Abu-Zeinah
Lancet Regional Health. Americas. 2026-09-01 - Sapablursen for Erythrocytosis Control in Patients with Polycythemia Vera.Jeanne M Palmer, Jonathan How, Prithviraj Bose, Pankit Vachhani, Adam J Mead
Blood. 2026-08-18 - Cross-study analyses of the ropeginterferon alfa-2b effect on phlebotomy in low- and high-risk patients with polycythemia vera.Anthony Michael Hunter, Albert Qin, Lucia Masarova, Ghaith Abu-Zeinah, Sung-Eun Lee
Leukemia & Lymphoma. 2026-07-17
Abstracts/Posters
- Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolit...Ruben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Standardized Equation Model of Quality of Life in Myeloproliferative NeoplasmsRuben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary MyelofibrosisRuben A Mesa, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- SOHO 2020: Bringing 'MPN Awareness' to Hematology CommunityMayo School of Continuous Professional Development, Phoenix, Arizona - 9/14/2013
- Pacritinib Demonstrates Efficacy Versus Best Available Therapy in Myelofibrosis Patients with Severe Thrombocytopenia in Two Phase 3 Studies61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Dynamic and Time-to-Event Analyses Demonstrate Marked Reduction in Transfusion Requirements for Janus Kinase Inhibitor_Na¥ve Myelofibrosis Patients Treated with Momelo...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Authored Content
- Watch: Momelotinib for Myelofibrosis — Top 10 Takeaways Physicians Should Know Post-FDA approvalSeptember 2023
- ASH 2020: An Explosion of Options for MPNs ForthcomingDecember 2020
Press Mentions
FDA Approves Ropeginterferon Alfa-2b-Njft for Essential ThrombocythemiaAugust 31st, 2026- Are We Measuring What Actually Matters? Rethinking Meaningful Outcomes in Cancer CareJuly 27th, 2026
- The Overlooked Complexity of Outpatient Cancer Care, Per 11 LeadersApril 13th, 2026
Grant Support
- Consumer-based meditation app, Calm, for treatment of sleep disturbance in hematological cancer patientsUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
- Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
- Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
- Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
- Cancer Center Support GrantWAKE FOREST UNIVERSITY HEALTH SCIENCES1997–2027
Professional Memberships
- Member
- Member
- Fellow
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
